Concentric's Clearance Not Likely to Spur Stroke Investment

The FDA's unexpected decision to issue market clearance for the first medical device to treat ischemic stroke, Concentric Medical's Merci retrieval system, is not likely to dramatically increase venture investing in stroke start-ups because of a wide range of challenges facing product development and adoption in this space.

The FDA's unexpected decision in mid-August to issue market clearance for Concentric Medical Inc. 's Merci retriever system, the first medical device approved by the agency to treat acute ischemic stroke (AIS), is a dramatic success for Concentric. It also boosts a field that has seen its share of disappointment and has only one other FDA approved treatment option.

The agency's decision was a surprise to many because just six months ago, the FDA's Neurological Devices Panel, while agreeing that the Merci system appeared efficacious, criticized Concentric for not...

More from Clinical Trials

More from R&D